IP Library › Granted Patent US 8,999,635
Granted Patent B2
US 8,999,635 · App. 12/097,493 · Granted Apr 7, 2015

Filaggrin

Inventors: William Henry Irwin McLean (Dundee, GB); Frances Jane Dorothy Smith (Dundee, GB)
Assignee: University Court of The University of Dundee
C12Q1/6883G01N33/6881G01N2800/122G01N2800/202G01N2800/205G01N2800/24C12Q2600/156C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,999,635
App. No.
12/097,493
Granted
Apr 7, 2015
Kind
B2
Abstract

The present invention relates to the identification of loss-of-function mutations in the filaggrin gene and their use in diagnosing ichthyosis vulgaris and/or susceptibility to other diseases including atopic dermatitis (eczema), asthma, psoriasis and allergies (including food allergy).

Claims (14)

1. A method for detecting ichthyosis vulgaris or a predisposition to ichthyosis vulgaris in a human subject comprising the step of:

detecting in a sample of nucleic acid from the subject the presence of a R501X mutation in the filaggrin gene using one or more of the primers selected from SEQ ID NO: 9, 10, 11, or 12; and

correlating the presence of the R501X mutation in the sample with detection of ichthyosis vulgaris or a predisposition to ichthyosis vulgaris in the subject.

2. A method for detecting atopic dermatitis or asthma in a human subject comprising the step of:

detecting in a sample of nucleic acid from the subject the presence of a R501X mutation in the filaggrin gene using one or more of the primers selected from SEQ ID NO: 9, 10, 11, or 12; and

correlating the presence of the R501X mutation in the sample with detection of atopic dermatitis or asthma in the subject.

3. The method according to claim 1 , wherein the nucleic acid is genomic DNA or mRNA.

4. The method according to claim 1 , wherein the human subject is a newborn or a fetus.

5. The method according to claim 1 , wherein the detection step comprises an analysis technique selected from the group consisting of: quantitative PCR, semi-quantitative PCR, real-time PCR, nucleic acid sequencing, hybridization studies, and restriction fragment length polymorphism (RFLP) analysis.

6. The method according to claim 1 , further comprising a step of identifying the number of filaggrin repeats in the filaggrin gene from the sample.

7. The method according to claim 2 , wherein the nucleic acid is genomic DNA or mRNA.

8. The method according to claim 2 , wherein the human subject is a newborn or a fetus.

9. The method according to claim 2 , wherein the detection step comprises an analysis technique selected from the group consisting of: quantitative PCR, semi-quantitative PCR, real-time PCR, nucleic acid sequencing, hybridization studies, and restriction fragment length polymorphism (RFLP) analysis.

10. The method according to claim 2 , further comprising a step of identifying the number of filaggrin repeats in the filaggrin gene from the sample.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2008
From: MCLEAN, WILLIAM HENRY IRWIN; SMITH, FRANCES JANE DOROTHY
To: UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE
Reel/Frame 021862/0289 →
Priority Claims (1)
GB 0525492.5 · Dec 15, 2005 · national
Continuity (1)
Related Publication 20100017896A1 · Jan 21, 2010